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AbstrACt
Objectives To report the distribution and predictors 
of insulin resistance (IR) in young people presenting to 
primary care-based mental health services.
Design Cross-sectional.
setting Headspace-linked clinics operated by the Brain 
and Mind Centre of the University of Sydney.
Participants 768 young people (66% female, mean age 
19.7±3.5, range 12–30 years).
Main outcome measures IR was estimated using 
the updated homeostatic model assessment (HOMA2-
IR). Height and weight were collected from direct 
measurement or self-report for body mass index (BMI).
results For BMI, 20.6% of the cohort were overweight 
and 10.2% were obese. However, <1% had an 
abnormally high fasting blood glucose (>6.9 mmol/L). 
By contrast, 9.9% had a HOMA2-IR score >2.0 
(suggesting development of IR) and 11.7% (n=90) 
had a score between 1.5 and 2. Further, there was a 
positive correlation between BMI and HOMA2-IR (r=0.44, 
p<0.001). Participants in the upper third of HOMA2-IR 
scores are characterised by younger age, higher BMIs 
and depression as a primary diagnosis. HOMA2-IR was 
predicted by younger age (β=0.19, p<0.001) and higher 
BMI (β=0.49, p<0.001), together explaining 22% of the 
variance (F
(2,361)=52.1, p<0.001).
Conclusions Emerging IR is evident in a significant 
subgroup of young people presenting to primary care-
based mental health services. While the major modifiable 
risk factor is BMI, a large proportion of the variance is not 
accounted for by other demographic, clinical or treatment 
factors. Given the early emergence of IR, secondary 
prevention interventions may need to commence prior 
to the development of full-threshold or major mood or 
psychotic disorders.
IntrODuCtIOn
The shortened life expectancy (in the range 
of 15–25 years) for those who live with major 
mental illness is largely driven by prema-
ture cardiovascular disease (pCVD).1–3 
pCVD is particularly notable for those with 
major depression, bipolar and psychotic 
disorders.4 5 Explanatory models include 
behaviourally linked risks (eg, daily tobacco 
smoking, reduced physical activity, increased 
sedentary behaviour, poor dietary habits and 
poor sleeping patterns),6–13 reduced access to 
healthcare14 15 and intrinsic central nervous 
system-driven perturbations of the hypotha-
lamic–pituitary axis, sympathetic nervous 
system activation and immune–inflammatory 
systems.16–19 
Recently, greater emphasis has been placed 
on the role of metabolic dysfunction in 
pCVD.20 For middle-aged cohorts living with 
chronic mental illness, the focus is on the 
longitudinal relationships between weight 
gain, central obesity and progressive insulin 
resistance (IR). It is assumed that there is 
a long lag-time between adolescent-onset 
of the mental illness (as 75% of mental 
disorders commence before age 25 years) 
secondary weight gain and changes in body 
fat composition and later onset of metabolic 
strengths and limitations of this study
 ► Observational and cross-sectional study of the dis-
tribution of insulin resistance  (IR) in a large cohort 
(n=768) of young people presenting for mental 
healthcare.
 ► Cross-sectional evaluation of demographic, clinical 
(diagnostic, medications) and body mass predictors 
of IR.
 ► Uses HOMA2-IR modelling of IR based on fasting 
insulin and fasting glucose.
 ► As there is significant heterogeneity in illness type, 
comorbidity and previous history of illness and med-
ication exposure, the findings are more relevant to 
similar cohorts presenting to primary  care as dis-
tinct from older or more diagnostically  homoge-
neous cohorts presenting to secondary or mental 
health specialist services.
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dysfunction.16 21 22 There is ongoing debate as to the role 
of exposure to psychotropic medications.23 24 In partic-
ular, second generation antipsychotics have been linked 
to an increase in a number of severe metabolic abnor-
malities,4 25 with these effects also being demonstrated in 
youth.26–28 Genetic studies have also identified a potential 
link between mood disorders and assorted cardiomet-
abolic diseases, suggesting shared biological and patho-
physiological mechanism.29
In Australia, we now have a variety of different early 
intervention mental health services that are located at 
various points along the illness course. Consequently, 
an important additional goal of these programmes is 
to improve physical health outcomes and reduce risk 
factors to pCVD.30 31 Early psychosis services, and linked 
at-risk programmes, typically manage clients in their 
early adult years. By this point, however, high rates of 
tobacco smoking, being overweight or obese and expo-
sure to psychotropic (antipsychotic and antidepressant) 
medications, are already common.32 Much current work 
is focused on modifying risks in this subpopulation of 
young people who are engaged with secondary care or 
more specialised mental health services.14 32 33
Through the development of the headspace 
programme, however, we now have the opportunity for 
intervening earlier with a much larger at-risk popula-
tion.34 These services engage younger cohorts (12–25 
years) with a broader range of (subthreshold and full-
threshold) anxiety, mood and psychotic syndromes. We 
have reported that this population also has some signif-
icant risk factors for pCVD, notably tobacco smoking, 
but that it is no more overweight than the general popu-
lation.35 Additionally, rates of increased fasting blood 
glucose (FBG) are minimal and, at this stage, there is no 
correlation between increasing body mass index (BMI) 
and FBG.35 The homeostatic model assessment of insulin 
resistance (HOMA2-IR) is a promising measure to indi-
cate risk for the development of metabolic dysfunction. 
Previous population-based reference ranges have gener-
ally been restricted to either child and adolescent (ie, 
under 18 years old)36 37 or adult samples.38–41 Suggested 
cut-offs for metabolic risk in these studies range from 
1.2 to 5.2 and do not span the young adult population 
of interest here. Only one study reports on HOMA-IR 
in healthy young people (aged 17–24 years), suggesting 
cut-offs of 2.9 and 2.3 for females and males, respectively. 
However, it is unclear the extent to which the distribu-
tion of IR in young people with mental health problems 
presenting for care deviates from comparable popula-
tion-based estimates.
Our earlier findings35 led us to suggest that, if we are to 
intervene early for metabolic dysfunction, we may need 
to consider alternative measures to BMI and FBG as the 
most useful tools for identifying individuals at highest 
risk of metabolic dysfunction or selecting cohorts for 
secondary prevention interventions. We hypothesised 
that a significant proportion of young people early in the 
course of their mental disorder are already developing IR 
as indicated by raised HOMA2-IR. Further, this perturba-
tion may be predicted by a broader range of demographic, 
clinical or treatment factors. Consequently, in this report, 
we describe the distribution of HOMA2-IR in this large 
headspace-based population and explore predictors of 
being in the upper third of that distribution.
MethODs
Cohort selection
Study participants were drawn from a larger cohort 
of young people presenting to one of the Brain and 
Mind Centre's youth mental health clinics that provide 
an integrated mix of primary-level services branded as 
headspace.34 42 These clinics attract young people with 
subthreshold and full-threshold mental disorders.42 Young 
people have been recruited to a research register for 
mood, psychotic, developmental and other mental disor-
ders and participated in a systematic surveillance process 
for assessing risks to metabolic, immune or cardiovascular 
disease between January 2005 and December 2017. All 
young people received clinician-based case management 
and relevant psychological, social and/or medical inter-
ventions over the duration of their time in care. Individ-
uals were included in the present study if they (1) were 
aged between 12 and 30 years of age at the time of initial 
assessment and (2) agreed to undertake systematic clin-
ical and laboratory screening for metabolic disturbance 
and risk to cardiovascular disease. Exclusion criteria were 
(1) lack of capacity to give informed consent (as deter-
mined by a psychiatrist), (2) clinically evident intellectual 
disability and/or insufficient English to participate in the 
research protocol or (3) current medical treatment for 
diabetes, thyroid or other active autoimmune disorders. 
All participants (or their guardians if under 16 years old) 
gave written informed consent for the use of routinely 
collected clinical data for research purposes.
As this is a high risk group for the development of meta-
bolic disease, and we have previously shown FBG alone to 
be insufficient as a screening instrument,35 it is standard 
practice to monitor FBG and insulin in this cohort. Partic-
ipants were included in this sample if a valid FBG and 
fasting insulin recording was available. Other clinical and 
metabolic measures were utilised when available.
Patient and public involvement
IBH is a member of the National Mental Health Commis-
sion, which has direct patient and family membership, 
and has prioritised a research effort to better inform 
practice that promotes detection and active management 
of risk factors to, and development of physical health 
problems, in patients with mental ill-health.43 IBH has 
also worked extensively with the National Heart Founda-
tion to examine the links between depression and cardio-
vascular disease and to improve integrated medical and 
psychiatric care.44–46 Our headspace centres have an active 
patient advisory panel who are consulted with regard to 
the development and application of research projects 
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within our service. This particular work is supported 
by funding directly from a patient and family founda-
tion, that supports our centre to investigate metabolic, 
hormonal and other physical health problems in young 
people with severe mood disorders. The results of the 
study are provided back directly to our service managers, 
and through our young persons advisory group, back to 
the users of our services
Clinical measures
Primary psychiatric diagnosis was assigned by the refer-
ring clinician or a research psychologist. Psychotropic 
medication use was obtained from clinician report, inter-
view or self-report.
Metabolic measures
Pathology requests were made by the referring clinician 
to obtain FBG and fasting insulin values. IR was estimated 
the updated homeostatic model assessment (HOMA2-IR) 
using iHOMA2 software V.8.8.47 Measures of height and 
weight were collected from direct measurement or self-re-
port for BMI calculation using the formula: weight(kg) ÷ 
height(m)2.
statistical analysis
Statistical analyses were performed using the SPSS V.24.0 
IBM. Continuous measures are reported as mean±SD. 
Percentages are followed by n in brackets, that is, % (n). 
Between-group comparisons were performed using inde-
pendent samples t-tests, one-way analysis of variance or χ2 
tests where relevant. Pearson’s correlations were used to 
examine associations between continuous variables.
As there are no currently established cut-offs for 
HOMA2-IR in this population, participants were split into 
groups based on tertiles of HOMA2-IR for comparisons 
across clinical, demographic and metabolic measures. 
In addition, participants were split into groups with 
HOMA2-IR <1.5, 1.5–2 and >2 to provide approximate 
comparisons to previously recommended HOMA-IR 
cut-offs. Multiple linear regression (using the ‘enter’ 
method) was used to quantify the relative associations 
between HOMA2-IR and any variables with significant 
associations at the univariate level. The following variables 
were log transformed prior to analyses to reduce posi-
tive skew: age, BMI, fasting glucose, fasting insulin and 
HOMA2-IR. All analyses were two tailed and employed an 
α level of 0.05.
results
The key measures of FBG and fasting insulin were avail-
able on 768 young people (66% female (n=510), mean 
age 19.7±3.5, range 12–30 years). These were used to 
calculate HOMA2-IR. For other measures: BMI was avail-
able on 364; details of concurrent psychotropic medica-
tion on 380; and primary clinical diagnosis on 430.
Those with BMI available were significantly older 
than those without BMI available (20.1±3.6 compared 
with 19.3±3.3 years old, t(766)=2.98, p=0.003) but the two 
groups did not differ on gender distribution, FBG, fasting 
insulin or HOMA2-IR (all p>0.05). Similarly, those with 
primary diagnosis information available were signifi-
cantly older than those without (20.2±3.6 compared 
with 19.0±3.2 years old, t(766)=4.7, p<0.001), and had 
lower fasting insulin (9.19±6.29 vs 9.97±6.7, t(766)=2.03, 
p=0.043) but did not differ on gender distribution, FBG, 
HOMA2-IR or BMI (all p>0.05). Likewise, those with 
medication information available were significantly older 
than those without (20.1±3.6 compared with 19.3±3.3 
years old, t(766)=3.3, p=0.001) but did not differ on gender 
distribution, FBG, fasting insulin, HOMA2-IR or BMI (all 
p>0.05).
For BMI, 9.9% (n=36) of participants were under-
weight (defined as <18.5), 59.3% (n=216) were in the 
normal range, 20.6% (n=75) were overweight (defined 
as >25) and 10.2% (n=37) were obese (defined as >30). 
Less than 1% of individuals (n=6) had an abnormally 
high FBG (>6.9 mmol/L) and only 1.4% (n=11) had 
FBG in the elevated range (5.6–6.9 mmol/L). For fasting 
insulin, 3.4% (n=26) recorded an abnormally high level 
(>25 mU/L) and 9.5% (n=73) had fasting insulin in 
the elevated range (15–25 mU/L). The distribution of 
HOMA2-IR is shown in figure 1. Mean HOMA2-IR (±SD) 
was 1.19±0.80. A HOMA2-IR score >2.0 was found in 
9.9% (n=76) and a score between 1.5 and 2 was found in 
11.7% (n=90).
While fasting glucose was higher in males (4.8±0.5 vs 
4.6±0.6 in females, t(766)=4.21, p<0.001) no differences 
were observed between sexes for insulin (males 9.7±7.2, 
females 9.5±6.1, t(766)=0.46, p=0.65), HOMA2-IR (males 
1.2±0.9, females 1.2±0.8, t(766)=0.60, p=0.55) or BMI 
(males 24.1±5.2, females 23.5±5.4, t(362)=1.11, p=0.27). 
There were small negative correlations between age 
and fasting insulin (r=−0.22, p<0.001) and HOMA2-IR 
(r=−0.21, p<0.001) but no correlation between age and 
fasting glucose (r=0.04, p=0.337). A positive correlation 
was evident between BMI and age (r=0.29, p<0.001). More 
importantly, there was a positive correlation between BMI 
and HOMA2-IR (r=0.44, p<0.001, see figure 2A), BMI 
and fasting insulin (r=0.43, p<0.001) and BMI and fasting 
glucose (r=0.11, p=0.03). Comparison of HOMA2-IR 
between BMI categories found significantly greater IR 
in those who were obese compared with all other BMI 
categories and overweight compared with all other BMI 
categories (F(3,360)=30.53, p<0.001, figure 2B). Differ-
ences between normal weight and underweight were not 
significant. Table 1 reports the proportion, age and sex 
distribution of individuals in each BMI category that have 
HOMA2-IR above or below 1.5.
The relationships between HOMA2-IR, split into 
tertiles and other demographic and clinical variables are 
shown in table 2. Of interest, those in the upper third of 
the HOMA2-IR distribution are characterised by younger 
age, higher BMIs, a lower proportion of persons with 
anxiety as a primary diagnosis and a higher proportion 
of persons with depression as a primary diagnosis (but 
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not bipolar or psychotic disorders). There were no clear 
relationships with specific psychotropic medication use. 
The overall regression model predicting HOMA2-IR 
from age and BMI was significant (F(2,361)=60.55, p<0.001) 
and explained 25% of the variance in HOMA2-IR. Both 
younger age (β=−0.27, b=−0.78, 95% CI −1.04 to −0.51, 
p<0.001) and higher BMI (β=0.51, b=1.23, 95% CI 1.04 to 
1.51, p<0.001) were significant predictors.
DIsCussIOn
This study of a large number of young people presenting 
to primary care-based mental health services reports 
the distribution of HOMA2-IR scores. These individuals 
present early in the clinical course of a broad admixture 
of anxiety, depressive, other mood or psychotic disorders 
and are known to be at high risk of developing meta-
bolic disorders and pCVD. Despite receiving medical 
and psychological treatments, at this stage of illness the 
cohort has comparable proportions who are overweight 
(21%) or obese (10%) to age-matched controls. In this 
cohort, <1% of individuals had an abnormally high FBG 
(>6.9 mmol/L) and only 1.4% had FBG in the elevated 
range (5.6–6.9 mmol/L). Further, there was no specific 
correlation between BMI and FBG.
By contrast, using HOMA2-IR as the index measure of 
developing IR, 10% have a score >2 and 22% have a score 
>1.5. Independent population-based studies of young 
people suggest that these ranges indicate being at risk of 
developing clinically significant IR.37 Mean HOMA2-IR in 
the present study was slightly lower than previous popula-
tion-based estimates in 18-year to 19-year olds48 and meta-
bolically healthy 17-year to 24-year olds,49 as well as adult 
samples.38–41 This indicates that, on average, the young 
people in the current study are not yet presenting with 
abnormal IR and associated risk for pCVD. Given the 
known elevated metabolic risk in this population of young 
people with mental illness, more research is needed to 
further elucidate early indicators of metabolic risk.
Consistent with other reports in young people,37 there 
is a significant correlation between BMI and HOMA2-IR 
(r=0.44, p<0.001) in the present study, and HOMA2-IR 
is best predicted by higher BMI and lower age, together 
Figure 1 Distribution of HOMA2-IR values. HOMA2-IR, homeostatic model assessment of insulin resistance.
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explaining 25% of the variance. In this cohort, being 
in the upper third of HOMA2-IR scores is predicted by 
higher BMI, younger age and having a primary diag-
nosis of depression. Reports in older population-based 
studies have noted associations between depressive symp-
toms and measures of IR.50 Previous research reports a 
transient increase in IR in early puberty,51 52 which may 
partially explain the association between younger age and 
IR in the present study.
Notably, being in the upper third of HOMA2-IR is not 
predicted by specific medication use, including expo-
sure to antidepressant or antipsychotic medications. 
When interpreting these findings, it is important to 
consider that drugs of different pharmacological classes 
(antidepressants, antipsychotics, mood stabilisers and so 
on) as well as those within the same class are associated 
with differential degrees of metabolic risk.53 54 Moreover, 
comparative to those undergoing pharmacotherapy 
for extensive periods of time, antipsychotic-naïve and 
first-episode patients may be more vulnerable to more 
immediate and aggressive cardiometabolic side effects.55 
Another possibility is that there are other unexpected 
relationships between those receiving pharmacotherapy 
and baseline BMI (eg, reluctance to prescribe specific 
medications (eg, mirtazapine, olanzapine) in those who 
are already overweight or obese). Clearly, those who are 
already overweight or obese may be at increased risk of 
developing IR if they are subsequently exposed to those 
Figure 2 (A) Correlation between BMI and HOMA2-IR. (B) Relationships between HOMA2-IR and BMI categories (n=364). 
BMI, body mass index; HOMA2-IR, homeostatic model assessment of insulin resistance.
Table 1 Number of cases in each BMI category and HOMA2-IR category above and below 1.5
Underweight, n=36 Normal weight, n=216 Overweight, n=75 Obese, n=37
HOMA2-IR <1.5 (n) 32 192 58 16
% of total sample 9 53 16 4
  % within BMI category 89 89 77 43
  Age (mean±SD) 18.7±3.3 19.8±3.4 21.4±3.3 22.6±3.8
  Sex (% female) 91 66 67 75
  Potential recommendations PWG WR, IA, AM-IR WR, IA, AM-IR
HOMA2-IR >1.5 (n) 4 24 17 21
% of total sample 1 7 5 6
  % within BMI category 11 11 23 57
  Age (mean±SD) 14.8±1.7 19.2±3.2 18.7±3.5 22.6±4.4
  Sex (% female) 50 62 59 57
  Potential recommendations AM-IR PWG, IA, AM-IR, WR, IA, AM-IR, WR, IA, AM-IR, Med
Total n=364.
HOMA2-IR,  homeostatic model assessment of insulin resistance; AM-IR, annual monitoring of insulin resistance (using HOMA2-IR); IA, 
increased physical activity; Med, medications, for example, metformin; PWG, prevent wt gain; WR, weight reduction.
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antidepressants or antipsychotics that have been specifi-
cally associated with weight gain or rapid onset of IR.
Due to the limitations of the clinical information 
collected pertaining to specific medication subtypes, 
doses and duration of medication use; no definitive 
conclusions pertaining to the effects of specific medica-
tions in predicting HOMA2-IR can be drawn from this 
cross-sectional study.
An important subgroup identified here was those who 
did not have evidence of IR despite being overweight 
(16%) or obese (4%). Other studies suggest that the 
metabolically healthy but obese individuals may be less 
sedentary and more physically active,56 and may also 
have a decreased risk of depression over time.57 Further 
higher IR levels have been reported previously in meta-
bolically unhealthy obese individuals.58 Our study is 
consistent with other reports that support the preposition 
that young overweight individuals are within the rela-
tively early stages of developing metabolic abnormalities, 
and that this may be detected more readily by abnormal 
insulin levels at a stage when glucose abnormalities are 
not yet indicative.59
As only 25% of the variance in HOMA2-IR in this youth 
mental health cohort is explained by known factors such 
as body composition and age (and possibly medication 
exposure in some subgroups), other clinical or patho-
physiologcal factors may be contributing to the risk of 
metabolic disturbance. If we are to develop effective inter-
vention and secondary prevention programmes to reduce 
the risk of pCVD, and specifically emerging metabolic 
disturbances, we need to track a direct measure—such 
as HOMA2-IR—through critical phases of illness onset, 
persistence and key transitions (such as exposure to 
psychotropic medications). We also need to explore what 
other factors may be driving this risk—such as perturbed 
circadian dysfunction, 24-hour sleep–wake and activity 
patterns, concurrent inflammatory or immune processes 
or dietary patterns, independent of specific diagnostic 
status.16 19 60
This study is limited by its cross-sectional design which 
does not allow assessment of longitudinal predictive rela-
tionships. In addition, potential selection bias due to the 
help-seeking nature of participants is likely. While the 
total sample with fasting insulin and glucose measures was 
large, additional clinical and metabolic measures were 
limited by the availability of the data collection method, 
and a measure of pubertal stage was not available. The 
results indicate that the sample with these measures was 
older than those without, which may also bias the find-
ings. However, it should be noted that there were no 
significant differences between these groups on gender 
distribution, or fasting insulin and glucose measures.
Current intervention programmes that only measure 
BMI or FBG, as well as focusing clinical outcome 
measurement on known risk factors (eg, reducing weight 
or increasing activity) do not have the capacity to assess 
effects on emerging IR, and thus it is not known whether 
such interventions are impacting the emergence of IR. 
Similarly, the impacts of prescribing specific medica-
tions (notably specific antidepressants or antipsychotics) 
to individuals at risk may well be contributing directly 
(and quickly) to emerging IR rather than indirectly 
(and slowly) via weight gain.23 24 Reliance on measures 
such as BMI or FBG appear to be inadequate means of 
tracking these changes. However, the optimal choice of 
objective measures can only be resolved by larger longitu-
dinal cohort, and relevant interventional studies. Future 
studies would benefit from a longitudinal design and the 
Table 2 Comparison of measures between HOMA2-IR tertiles
1. Lower tertile
(HOMA2-IR: 
0.36–0.78)
(n=259)
2. Middle tertile
(HOMA2-IR: 
0.78–1.24)
(n=257)
3. Higher tertile
(HOMA2-IR: 
1.24–7.41)
(n=252) Statistics (ANOVA or χ2)
Significant pairwise 
comparisons
Age 20.5±3.3 19.7±3.3 18.8±3.6 F(2,765)=17.1, p<0.001 3<2<1
Sex (% female) 63.7 67.7 67.9 χ2=1.3, p=0.53
Metabolic 
measures
BMI 21.8±3.2 23.5±4.6 26.4±6.8 F(2,361)=23.8, p<0.001 1<2<3
Fasting glucose 4.5±0.4 4.7±0.4 4.9±0.8 F(2,765)=40.67, p<0.001 1<2<3
HOMA2-IR 0.6±0.1 1.0±0.1 2.0±0.9 F(2,765)=1260.51, p<0.001 1<2<3
Primary 
diagnosis
% Anxiety 35.4 20.7 26.5 χ2=8.2, p=0.02
% Depression 35.4 47.9 51.5 χ2= 8.5, p=0.01
% Bipolar 15.2 16.4 12.1 χ2=1.1, p=0.59
% Psychosis 6.3 2.9 3.8 χ2=2.3, p=0.32
Medication % Any medication 53.2 46.8 50.4 χ2=1.1, p=0.58
% Antidepressants 34.8 29.8 31.9 χ2=0.8, p=0.68
% Antipsychotics 19.1 20.2 18.3 χ2=0.1, p=0.93
% Mood stablilsers 10.6 12.9 18.3 χ2=3.2, p=0.20
BMI, body mass index; HOMA2-IR, homeostatic model assessment of insulin resistance.
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inclusion of additional physical health measures such 
as smoking status, dietary patterns, inflammatory and 
immune measures and 24-hour sleep–wake and activity 
patterns.
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